Sino Biological Respiratory Virus Research Toolkit
 

Anti-SARS-CoV-2 NeutraLISA

Anti-SARS-CoV-2 NeutraLISA

Principle: ELISA based on competitive binding of neutralising antibodies in the sample and labelled ACE2 receptors to S1/RBD

Automation: YES

Approvals: CE-IVD

Suitability: Supports analysis of the immune response after SARS-CoV-2 infection or vaccination

Description:

Surrogate virus neutralisation test (sVNT) for determination of neutralising antibodies that inhibit the binding of SARS-CoV-2 S1/RBD to ACE2 receptors


Key Points:
  • 100% agreement of results compared with plaque reduction neutralisation test (PRNT50)
  • Established ELISA method – suitable for routine laboratory diagnostics, no BSL-3 conditions required
  • Automatable even for high-throughput analysis, results available in 2 hours

Areas:

    Clinical
Company contact details:

EUROIMMUN AG view full details
Lübeck
Germany

Website: Visit Website
Tel: +49 451 2032-0